Northern Trust Corp Has $17.26 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Northern Trust Corp grew its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 620,321 shares of the company's stock after purchasing an additional 35,737 shares during the period. Northern Trust Corp owned 0.89% of Akero Therapeutics worth $17,257,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AKRO. The Manufacturers Life Insurance Company increased its holdings in shares of Akero Therapeutics by 29.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 124,592 shares of the company's stock worth $3,466,000 after acquiring an additional 28,043 shares during the period. Quarry LP acquired a new stake in shares of Akero Therapeutics in the 4th quarter worth about $83,000. Aquatic Capital Management LLC increased its holdings in shares of Akero Therapeutics by 463.8% in the 4th quarter. Aquatic Capital Management LLC now owns 18,041 shares of the company's stock worth $502,000 after acquiring an additional 14,841 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Akero Therapeutics in the 4th quarter worth about $233,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Akero Therapeutics by 13.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,321,972 shares of the company's stock worth $120,238,000 after acquiring an additional 513,613 shares during the period.

Insider Activity

In other news, COO Jonathan Young sold 607 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $27,242.16. Following the completion of the transaction, the chief operating officer now owns 200,540 shares in the company, valued at approximately $9,000,235.20. This trade represents a 0.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Patrick Lamy sold 1,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $48.09, for a total transaction of $48,090.00. Following the transaction, the vice president now owns 33,492 shares of the company's stock, valued at approximately $1,610,630.28. This trade represents a 2.90% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 219,208 shares of company stock worth $9,218,994. Corporate insiders own 7.94% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Citigroup dropped their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. UBS Group increased their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. HC Wainwright increased their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Bank of America raised shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $82.33.

Akero Therapeutics Price Performance

Akero Therapeutics stock traded down $1.09 during trading hours on Friday, hitting $38.87. 1,307,830 shares of the company traded hands, compared to its average volume of 911,743. The firm has a market cap of $3.10 billion, a P/E ratio of -10.37 and a beta of -0.12. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm's 50-day simple moving average is $40.85 and its two-hundred day simple moving average is $37.83. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of ($1.01) by $1.91. As a group, analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.